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Epidermal growth factor receptor (EGFr) is a 170 kD
phosphoglycoprotein which spans the cell membrane and
mediates the initial response of a wide range of cells to the
peptide growth hormone EGF (Carpenter & Cohen, 1979;
Cohen, 1983). Transforming growth factor a (TGFa) which
is structurally related to EGF, also binds to EGFr to initiate
a mitogenic response (Marquardt et al., 1983). Over-
expression of EGFr has been associated with malignant
transformation of epidermal cells (Ozenne et al., 1986) and
with the metastatic potential of breast (Sainsbury et al.,
1985) and lung cancer (Veale et al., 1987). The receptor also
plays an important role in the regulation of growth and
differentiation of epidermal cells both in tissue culture and in
vivo.
The aim of this study was to characterise EGFr expression
in a number of foetal tissues, to determine the suitability of
each tissue for further study on the role of EGFr in
oncogenesis.
Fresh tissue samples were obtained from normal foetuses
immediately after prostaglandin-induced terminations.
Twenty-six cases of 14-19 weeks estimated gestational age
(EGA) were studied. Age was assessed by menstrual history
and clinical examination together with foetal weight, crown-
rump measurement and foot length. Biopsies were snap
frozen and 5-7,um cryostat sections mounted on gelatin-
coated slides: these were air-dried and fixed in acetone for
20min at room temperature. The EGFr was identified in the
unlabelled peroxidase antiperoxidase (PAP) immunohisto-
chemical method, first described by Sternberger et al. (1970).
The primary monoclonals used were MAS 6580 (Sera Lab)
which binds to the external portion of the EGFr molecule
(Yarden et al., 1985) and EGFR1 (Amersham) that recog-
nizes an antigenic determinant located on the polypeptide
chain of the receptor (Mayes & Waterfield, 1984). Sections
were incubated at room temperature with primary antibody
at a dilution of 1/100 (MAS 6580c) for 60min or at 4°C at a
dilution of 1/50 (EGFRI) overnight. After washing these
were incubated with rabbit anti-mouse Ig (Dakopatts 1:20)
in 20% normal human AB serum for 30min, followed by a
30min incubation with 1/100 dilution of PAP complex
(Dakopatts). The bound peroxidase was visualized using the
diaminobenzidine/H202 reaction. Sections werecounterstained
in Harris' haematoxylin, dehydrated and mounted in DPX.
Controls included the replacement of primary antibody with
Tris buffered saline or normal mouse immunoglobulin. In
addition normal adult skin and term placenta sections were
run as known EGFr positive controls and adult lymphocyte
preparations as known EGFr negative controls.
The intensity of staining was assessed and graded on a
scale from 0 to + +. Control slides were uniformly negative,
except known adult skin and term placenta (Figure 1). Cells
that were found to be predominantly positive for EGFr are
indicated in Table I for each tissue. The staining pattern
observed was similar for both EGFr antibodies.
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Figure 1 EGFr expression in foetal tissue using the PAP
procedure with MAS 6580c antibody. (a) Foetal lung (18 weeks
EGA) showing EGFr positive cells of the bronchial epithelium
and alveoli. (b) Foetal lung (16 weeks EGA) negative for EGFr.
(c) Foetal kidney (18 weeks EGA) showing EGFr positive cells
of the distal and proximal tubules and EGFr negative glomeruli.
(d) Term placenta positive for EGFr (x 550).
Figure 2 EGFr expression in foetal skin revealed using the PAP
procedure with EGFRI antibody. (a) At 16 weeks EGA showing
low intensity staining of the keratinocytes ( x 275). (b) at 18
weeks EGA showing high intensity staining of the keratinocytes
for EGFr ( x 550).
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Table I Epidermal growth factor receptor expression in foetal tissues
Age/weeks
14/15 16 17 18 19
Tissue Staining pattern (5) (5) (8) (3) (5)
Adrenal Luminal border of cortical 0 0 0/+ ++ ++
cells (3/5)
Bladder Mucosal epithelial cells 0 0 + ++ ++
Blood Lymphocytes and monocytes 0 0 0 0 0
Gut Epithelial cells of villi 0 + + + + + +
Heart Myocardial+vessel endothelial 0 0 0/+ + + + +
cells (2/6)
Kidney Distal and proximal tubule cells 0 0 + + + + +
Liver Haemopoietic cells 0 + + + + + + +
Lung Cells of the bronchial 0 0 0/+ + + + +
epithelia and alveoli (2/6)
Pancreas Exocrine cells and vessel 0 0 0/+ + + + +
endothelial cells
Skin Keratinocytes and dermal 0 + + + + + +
(abdominal and dorsal) skin appendages
Spleen Haemopoietic cells 0 + +/+ + + + + +
(2/6)
Stomach Cells of mucosa and wall 0 0 + + + + +
Testes (8) Epithelial cells 0 0 + + + + +
Thymus Epithelial cells in cortex
and medulla 0 + + + + + +
Thyroid Follicular cells 0 + + + + + +
Ureter Epithelial lining cells 0 + + + + + +
The number in brackets indicates the number of foetuses examined at each time point with the
staining pattern observed. 0=negative. + =low intensity staining. + + =high intensity staining.
The EGFr was detected on the majority of foetal tissue
studied at 17 weeks EGA and above (Table I). However, the
receptor was not expressed prior to 17 weeks EGA, except in
the skin, gut, liver, thyroid and spleen where weak staining
(+) was observed at 16 weeks EGA. By 18 weeks EGA
intense staining (+ +) for the receptor was observed on all
tissues studied particularly on epithelial cells (Table I,
Figures 1 and 2). These results indicate significant EGFr
gene expression in the foetus at around 17 weeks EGA.
A study of adult tissue has shown a large number of
tissues to be EGFr positive, with the exception of the
adrenal and thyroid (Damjanov et al., 1986). This is of
interest, as it suggests in the light of the present findings that
EGFr gene expression probably becomes repressed in
adrenal and thyroid tissues at times beyond those of positive
detection in the foetal samples. In the adult, it was shown
that actively proliferating epithelia expressed EGFr at the
cell surface whereas once cells differentiated into a non-
proliferating component, EGFr expression was reduced to
undetectable levels or extinguished (Damjanov et al., 1986).
Whether other receptors determine growth before 16-17
weeks EGA is at present unknown.
Analysis of DNA from squamous carcinoma cell lines and
tumours has revealed that amplification of the gene encoding
the EGFr is associated with over-expression of the receptor
in these cells (Ozanne et al., 1986). Whether the EGFr gene
in foetal tissue is 'switched-on' by some regulatory mechan-
ism or simply amplified is open to speculation. Over-
expression is not a consequence ofproliferation per se, as the
receptor is not increased in hyperproliferative skin disorders
(Ozanne et al., 1985). Malignant and virally transformed
epidermal cells possess 5-50 times more EGFr than normal
keratinocytes (Cowley et al., 1986). Therefore, the increased
expression of EGFr in epidermal malignancies may be an
important component of the malignant phenotype in these
tumours. Cancerous tissue in the lung has also been shown
to have significantly increased levels of EGFr compared to
normal lung (Veale et al., 1987) and amplification of the
EGFr gene (Berger et al., 1987). The level of EGFr is also
associated with the degree of invasion and poor differentia-
tion of bladder cancer (Neal et al., 1985). It has thus been
suggested that the presence of this receptor on squamous cell
carcinomas may prove to be of diagnostic value and a
suitable target for therapy, yet little is understood about the
exact role of the receptor in oncogenesis. We propose to
utilize the availability of foetal tissue which is either negative
or positive for EGFr to investigate the role of the receptor in
malignant cell transformation.
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